254750-02-2

Usage

Uses

Used in Pharmaceutical Industry:
Emricasan is used as a therapeutic agent for the treatment of various conditions associated with caspase-mediated apoptosis and inflammation. It has shown potential in reducing hepatic injury and liver fibrosis, making it a promising candidate for the treatment of liver diseases.
Used in Anti-apoptotic Applications:
As an irreversible pan-caspase inhibitor, Emricasan is used to prevent caspase-mediated apoptosis, which is a form of programmed cell death. This property makes it useful in the treatment of conditions where excessive apoptosis contributes to tissue damage or disease progression.
Used in Anti-inflammatory Applications:
Emricasan also has anti-inflammatory effects by inhibiting caspase-mediated inflammation pathways. This makes it a potential treatment option for inflammatory disorders where caspase activation contributes to the disease process.

InChI:InChI=1/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1

Upstream product

• 409369-36-4 (3S)-3-[N-(N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid benzyl ester 
• 68259-67-6 N-Pyruvoyl-L-alanin-methylester 
• 2392-63-4 N-Pyruvyl-L-alanin 
• 254751-08-1 2-((2-(tert-butyl)phenyl)amino)-2-oxoacetic acid 
• 483334-60-7 methyl 2-[N-(2-tert-butylphenylamino)]-2-oxoacetate 
• 3408-50-2 [(N-benzyloxycarbonyl)-L-alaninyl]-L-aspartic acid [beta]-tert-butyl ester 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 254750-82-8 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 868565-57-5 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 
• 868565-58-6 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 254750-81-7 (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 868565-55-3 (3S)-3-[(N-benzyloxycarbonyl)-L-alaninyl]amino-5-bromo-4-oxopentanoic acid tert-butyl ester 
• 254750-83-9 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 

Relevant academic research and scientific papers

A the graciousness favorable card lives synthetic method

A synthetic method for emricasan belongs to the technical field of drug chemical synthesis. The synthetic method comprises the steps: firstly carrying out acyl chlorination reaction on pyruvic acid and an acyl chlorination reagent to obtain pyruvoyl chlor

METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE

Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions

CRYSTALLINE FORMS OF ( 3 S ) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANIWYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-0X0PENTA NOIC ACID

The present invention relates to crystalline forms of (3S)-3-[N-(N'-(2-tert- butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid (see formula (I)). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis.

First-in-class pan caspase inhibitor developed for the treatment of liver disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.